JPY 610.0
(-0.65%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | -1.54 Billion JPY | 36.95% |
2022 | -2.44 Billion JPY | 23.95% |
2021 | -3.21 Billion JPY | -200.65% |
2020 | -1.06 Billion JPY | -121.85% |
2019 | -482 Million JPY | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q1 | -2.12 Billion JPY | -37.91% |
2023 Q2 | -1.86 Billion JPY | 8.37% |
2023 Q4 | -1.54 Billion JPY | 7.34% |
2023 Q3 | -1.66 Billion JPY | 10.85% |
2023 FY | -1.54 Billion JPY | 36.95% |
2023 Q1 | -2.03 Billion JPY | 16.71% |
2022 Q3 | -2.61 Billion JPY | 7.42% |
2022 FY | -2.44 Billion JPY | 23.95% |
2022 Q4 | -2.44 Billion JPY | 6.36% |
2022 Q2 | -2.82 Billion JPY | 0.0% |
2021 FY | -3.21 Billion JPY | -200.65% |
2020 FY | -1.06 Billion JPY | -121.85% |
2019 FY | - JPY | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
Kyowa Kirin Co., Ltd. | -378.83 Billion JPY | 99.593% |
Astellas Pharma Inc. | 670.02 Billion JPY | 100.23% |
Chugai Pharmaceutical Co., Ltd. | -445.21 Billion JPY | 99.654% |
Ono Pharmaceutical Co., Ltd. | -157.27 Billion JPY | 99.02% |
Santen Pharmaceutical Co., Ltd. | -59.42 Billion JPY | 97.406% |
JCR Pharmaceuticals Co., Ltd. | 4.54 Billion JPY | 133.922% |
Daiichi Sankyo Company, Limited | -259.26 Billion JPY | 99.405% |
Otsuka Holdings Co., Ltd. | -299.15 Billion JPY | 99.485% |